ST吉药(300108) - 2019 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2019 reached ¥299,392,674.72, representing an increase of 118.31% compared to ¥137,142,568.38 in the same period last year[8] - Net profit attributable to shareholders decreased by 18.72% to ¥28,883,003.58 from ¥35,535,022.45 year-on-year[8] - Net profit excluding non-recurring gains and losses fell by 55.27% to ¥5,343,040.55 from ¥11,944,901.04 in the previous year[8] - The basic earnings per share decreased by 20.00% to ¥0.04 from ¥0.05 year-on-year[8] - The weighted average return on equity was 1.31%, down from 1.81% in the previous year[8] - Net profit for the current period was ¥28,585,467.21, down from ¥35,535,022.45 in the previous period, indicating a decrease of approximately 19.6%[57] - Earnings per share (EPS) for the current period was ¥0.04, compared to ¥0.05 in the previous period, showing a decline of 20%[59] Cash Flow and Liquidity - Operating cash flow improved significantly, with a net cash flow from operating activities of ¥184,559,901.94, a 753.40% increase from -¥28,245,963.60 in the same period last year[8] - Cash inflow from operating activities reached ¥468,976,077.31, significantly up from ¥127,334,629.45 in the prior period, marking an increase of approximately 267%[66] - The net cash flow from operating activities was ¥184,559,901.94, a recovery from a negative cash flow of ¥28,245,963.60 in the same period last year[67] - Cash and cash equivalents at the end of the period amounted to ¥377,186,830.10, an increase of 80.92% compared to the beginning of the period, primarily due to increased bank borrowings[20] - The ending balance of cash and cash equivalents was ¥377,186,830.10, down from ¥460,192,119.83 at the end of the previous period[71] - The company reported a net cash increase of ¥168,704,001.78 for the quarter, compared to an increase of ¥90,345,844.12 in the previous period[71] Assets and Liabilities - Total assets increased by 4.33% to ¥5,062,902,145.46 from ¥4,852,817,985.94 at the end of the previous year[8] - Total liabilities increased significantly, with long-term borrowings at the end of the period reaching ¥801,000,000.00, up 33.3% from ¥601,000,000.00 at the beginning of the period[21] - Total liabilities amounted to ¥1,164,197,411.39, an increase from ¥1,099,794,110.24 in the previous period, representing a growth of about 5.9%[53] - The total liabilities of the company were CNY 2,785,484,087.04, compared to CNY 2,604,319,234.41 at the end of 2018, which is an increase of approximately 6.9%[43] - Long-term borrowings increased to ¥300,000,000.00 from ¥150,000,000.00 in the previous period, reflecting a growth of 100%[53] Operational Highlights - Operating revenue for the period was ¥299,392,674.72, representing a 118.3% increase from ¥137,142,568.38 in the same period last year, mainly due to the consolidation of newly acquired subsidiaries[22] - Operating costs for the period were ¥233,624,790.30, an increase of 154.1% compared to ¥91,948,389.72 in the same period last year, primarily due to the consolidation of newly acquired subsidiaries[22] - Cash received from sales of goods and services was ¥202,403,833.03, up 108.1% from ¥97,245,638.70 in the same period last year, mainly due to the consolidation of newly acquired subsidiaries[24] - The company reported a significant increase in sales expenses, which amounted to ¥18,016,113.92, a 213.8% increase from ¥5,741,519.87 in the same period last year, primarily due to the consolidation of newly acquired subsidiaries[22] - The company has adjusted its pharmaceutical product structure to focus on high-margin products, resulting in a reduction of low-margin product production and sales channels[27] - The OTC product sales strategy is expected to achieve scale effects in 2019, with a focus on enhancing competitive advantages in the market[27] Investment and Financing Activities - Investment cash outflows surged to CNY 406,974,266.19, a 408.7% increase from CNY 80,000,000.00 in the previous year, mainly due to the acquisition of equity in Changchun Puhua Pharmaceutical Co., Ltd.[25] - The company secured bank loans totaling CNY 694,000,000.00, marking a 161.9% increase from CNY 265,000,000.00 in the same period last year, driven by increased bank borrowing[26] - Cash used for debt repayment reached CNY 226,800,000.00, a 100.9% increase from CNY 112,887,576.58 year-on-year, primarily due to higher bank loan repayments[26] - The company received cash from borrowings amounting to ¥694,000,000.00, compared to ¥265,000,000.00 in the previous period, indicating a significant increase in financing[69] Other Financial Metrics - The company received government subsidies amounting to ¥27,714,618.25 during the reporting period[9] - The company reported a total of ¥27,714,618.25 in other income, slightly down from ¥28,237,341.25 in the previous period, indicating a decrease of about 1.8%[54] - The total amount of contract liabilities was ¥864,197,411.39, compared to ¥949,794,110.24 in the previous period, showing a decrease of approximately 9%[53] - Research and development expenses for the current period were ¥4,476,308.16, compared to ¥2,221,900.58 in the previous period, marking an increase of about 101.4%[54] - The company reported no violations regarding external guarantees during the reporting period[36] - There were no significant changes in net profit expected compared to the same period last year[36]